Privium Fund Management B.V. Buys 18,763 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Privium Fund Management B.V. lifted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQTFree Report) by 5.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 344,472 shares of the company’s stock after buying an additional 18,763 shares during the period. Arcutis Biotherapeutics makes up approximately 1.0% of Privium Fund Management B.V.’s holdings, making the stock its 16th largest holding. Privium Fund Management B.V. owned about 0.29% of Arcutis Biotherapeutics worth $4,736,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Arcutis Biotherapeutics by 3.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,697 shares of the company’s stock worth $464,000 after purchasing an additional 917 shares during the period. Amalgamated Bank increased its holdings in Arcutis Biotherapeutics by 39.4% during the 1st quarter. Amalgamated Bank now owns 3,723 shares of the company’s stock valued at $58,000 after purchasing an additional 1,053 shares during the period. Tocqueville Asset Management L.P. raised its position in Arcutis Biotherapeutics by 14.1% during the 1st quarter. Tocqueville Asset Management L.P. now owns 16,200 shares of the company’s stock valued at $253,000 after purchasing an additional 2,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Arcutis Biotherapeutics by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after buying an additional 2,063 shares during the period. Finally, LVW Advisors LLC grew its position in shares of Arcutis Biotherapeutics by 21.4% in the 2nd quarter. LVW Advisors LLC now owns 17,561 shares of the company’s stock worth $246,000 after buying an additional 3,095 shares during the last quarter.

Insider Buying and Selling

In other news, insider Masaru Matsuda sold 36,130 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $16.16, for a total value of $583,860.80. Following the sale, the insider directly owned 161,234 shares of the company’s stock, valued at approximately $2,605,541.44. This represents a 18.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Larry Todd Edwards sold 4,504 shares of the firm’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $20.04, for a total value of $90,260.16. Following the transaction, the insider owned 178,897 shares of the company’s stock, valued at $3,585,095.88. The trade was a 2.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 154,386 shares of company stock worth $2,640,187 over the last three months. Corporate insiders own 9.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. The Goldman Sachs Group began coverage on Arcutis Biotherapeutics in a report on Friday, July 25th. They set a “neutral” rating and a $18.00 target price for the company. Needham & Company LLC raised their target price on shares of Arcutis Biotherapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Wall Street Zen raised shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Arcutis Biotherapeutics in a research note on Tuesday, October 14th. Finally, Cowen restated a “buy” rating on shares of Arcutis Biotherapeutics in a report on Thursday, August 7th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Arcutis Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.80.

Read Our Latest Research Report on ARQT

Arcutis Biotherapeutics Price Performance

NASDAQ:ARQT opened at $20.88 on Tuesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.20 and a quick ratio of 3.04. The firm’s 50-day moving average price is $17.77 and its 200-day moving average price is $15.40. The company has a market capitalization of $2.50 billion, a PE ratio of -27.84 and a beta of 2.06. Arcutis Biotherapeutics, Inc. has a 1-year low of $8.03 and a 1-year high of $21.84.

Arcutis Biotherapeutics (NASDAQ:ARQTGet Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. The business had revenue of $81.50 million for the quarter, compared to analyst estimates of $72.70 million. Arcutis Biotherapeutics had a negative net margin of 35.40% and a negative return on equity of 62.62%. On average, equities analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current fiscal year.

Arcutis Biotherapeutics Company Profile

(Free Report)

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

Further Reading

Want to see what other hedge funds are holding ARQT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQTFree Report).

Institutional Ownership by Quarter for Arcutis Biotherapeutics (NASDAQ:ARQT)

Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.